Omeros Corp (OMER)

$10.74 -0.77 (-6.69%)
Market Cap 816.06M
Revenue (ttm) 0.00
Net Income (ttm) -156.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.80
Volume 1,819,000
Avg Vol 2,731,632
Day's Range N/A - N/A
Shares Out 70.90M
Stochastic %K 9%
Beta 2.44
Analysts Sell
Price Target $43.67

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
AVCTQBNAPL
AVCTQBNAPL Feb. 6 at 10:37 AM
$OMER Any updates on the buyout?
0 · Reply
naturegirl669
naturegirl669 Feb. 6 at 8:25 AM
$OMER - Capitulation in stocks occurs when investors succumb to fear and panic, selling their holdings in a massive, high-volume wave to avoid further losses, typically near the end of a sharp, sustained downtrend. It represents the "throwing in the towel" moment, often signaling a market bottom, or "selling climax," as weak hands exit and value-focused investors begin buying.
0 · Reply
WinstonWolfff
WinstonWolfff Feb. 6 at 3:30 AM
$OMER 📋 Institutions & Firms Reported With Short Positions In Omeros According to aggregated short-interest data sources, the following institutional investors and trading firms have reported short positions in OMER: 🔹 Firms Identified With Short Exposure Susquehanna International Group LLP — a large proprietary trading and market-making firm known for active short positioning. Citadel Advisors LLC — major hedge fund and market maker frequently involved in short trading and derivatives strategies. Caption Management LLC — hedge fund identified in short reporting. Jefferies Financial Group Inc. — investment bank/trading desk reported with a short interest. Group One Trading LLC — proprietary trading group with reported OMER short exposure. Key point: these names are based on publicly reported short positions (often via short-interest reporting vendors), but they do not disclose exact number of shares shorted per firm in real time.
1 · Reply
resq1
resq1 Feb. 5 at 10:40 PM
$OMER you guys all know that it's not every day that a rare disease drug gets full FDA approval w/o black label warnings and approved for pediatric patients, right?
1 · Reply
in_GOD_alone
in_GOD_alone Feb. 5 at 10:09 PM
$OMER need a beer y’all.
0 · Reply
What_the_heck_is_that
What_the_heck_is_that Feb. 5 at 8:39 PM
$OMER it's one thing to be down in sympathy with the market but to steadily watch a slow crash since the first of the year in the absence of any negative news whatsoever is just mind boggling. I'm also not exactly sure why the next ER has to occur at the tail end of March either, since the last one was in Nov 2025 and 3 months later would logically put a 'quarterly' report sometime in Feb, not March, and especially not the very last day of March as anticipated 🤷. Regardless, it's going to take hard sales figures to drive this upward, not just a PR that says "hey, we're distributing the product". That unfortunately leaves room for speculation that the drug might not be getting the expected traction. I'm holding on still but those who sold at $17+ at least made decent profit even if the SP climbs higher in the future. You won't go broke selling over your average but you definitely could go broke hanging on for dear life wondering what's wrong.
3 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 5 at 8:38 PM
$ONDS $OMER $IBRX sweet baby Moses… 🤣😂😵‍💫😘
0 · Reply
MattyMoMo
MattyMoMo Feb. 5 at 8:32 PM
$OMER OMER is being treated like an AI or tech stock today.
0 · Reply
mjk49
mjk49 Feb. 5 at 8:28 PM
$OMER @ipdamages Is this dropping this low because of trumpRX and news related to that?
1 · Reply
BioBomber
BioBomber Feb. 5 at 8:28 PM
$OMER We were higher than this 2 months ago before approval. It’s laughable at this point, bought another 5k shares.
0 · Reply
Latest News on OMER
Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 9 days ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Jan 7, 2026, 9:07 PM EST - 4 weeks ago

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 4 weeks ago

Omeros prices transplant complication drug at $36,000 per dose

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 26, 2025, 6:36 PM EST - 5 weeks ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Dec 24, 2025, 2:14 PM EST - 6 weeks ago

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Gold Edges Lower; Omeros Shares Jump

Dec 24, 2025, 12:21 PM EST - 6 weeks ago

Gold Edges Lower; Omeros Shares Jump

AAAU BAR DBP GLD GLDM IAU OUNZ

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:05 AM EST - 6 weeks ago

US FDA approves Omeros' drug to treat dangerous transplant complication

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 24, 2025, 9:00 AM EST - 6 weeks ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Dec 1, 2025, 8:30 AM EST - 2 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Nov 17, 2025, 10:37 AM EST - 2 months ago

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 3 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Nov 11, 2025, 8:30 AM EST - 3 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Oct 17, 2025, 4:43 PM EDT - 3 months ago

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

Oct 16, 2025, 10:08 AM EDT - 4 months ago

Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case

NVO

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 16, 2025, 8:30 AM EDT - 4 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Oct 15, 2025, 2:58 PM EDT - 4 months ago

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

NVO

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 11:54 AM EDT - 4 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

Oct 15, 2025, 9:17 AM EDT - 4 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Oct 15, 2025, 8:32 AM EDT - 4 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Oct 15, 2025, 8:30 AM EDT - 4 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Sep 2, 2025, 8:45 AM EDT - 5 months ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 4:41 PM EDT - 6 months ago

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:02 PM EDT - 6 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Aug 11, 2025, 4:02 PM EDT - 6 months ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jul 25, 2025, 8:00 AM EDT - 6 months ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Jun 27, 2025, 8:30 AM EDT - 7 months ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Jun 24, 2025, 8:30 AM EDT - 8 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Jun 10, 2025, 12:53 PM EDT - 8 months ago

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

May 27, 2025, 11:12 PM EDT - 9 months ago

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 9 months ago

Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript

Omeros Corporation Reports First Quarter 2025 Financial Results

May 15, 2025, 4:05 PM EDT - 9 months ago

Omeros Corporation Reports First Quarter 2025 Financial Results

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 5:05 PM EDT - 9 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 12, 2025, 10:35 AM EDT - 9 months ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

May 6, 2025, 9:16 AM EDT - 9 months ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Apr 11, 2025, 3:06 PM EDT - 10 months ago

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 10, 2025, 9:10 AM EDT - 10 months ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Apr 8, 2025, 9:00 AM EDT - 10 months ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:57 PM EDT - 11 months ago

Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 31, 2025, 4:02 PM EDT - 11 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Mar 28, 2025, 7:39 AM EDT - 11 months ago

Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 26, 2025, 9:15 AM EDT - 11 months ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Mar 21, 2025, 9:15 AM EDT - 11 months ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Feb 24, 2025, 4:44 PM EST - 1 year ago

Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Dec 19, 2024, 12:28 PM EST - 1 year ago

Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

AVCTQBNAPL
AVCTQBNAPL Feb. 6 at 10:37 AM
$OMER Any updates on the buyout?
0 · Reply
naturegirl669
naturegirl669 Feb. 6 at 8:25 AM
$OMER - Capitulation in stocks occurs when investors succumb to fear and panic, selling their holdings in a massive, high-volume wave to avoid further losses, typically near the end of a sharp, sustained downtrend. It represents the "throwing in the towel" moment, often signaling a market bottom, or "selling climax," as weak hands exit and value-focused investors begin buying.
0 · Reply
WinstonWolfff
WinstonWolfff Feb. 6 at 3:30 AM
$OMER 📋 Institutions & Firms Reported With Short Positions In Omeros According to aggregated short-interest data sources, the following institutional investors and trading firms have reported short positions in OMER: 🔹 Firms Identified With Short Exposure Susquehanna International Group LLP — a large proprietary trading and market-making firm known for active short positioning. Citadel Advisors LLC — major hedge fund and market maker frequently involved in short trading and derivatives strategies. Caption Management LLC — hedge fund identified in short reporting. Jefferies Financial Group Inc. — investment bank/trading desk reported with a short interest. Group One Trading LLC — proprietary trading group with reported OMER short exposure. Key point: these names are based on publicly reported short positions (often via short-interest reporting vendors), but they do not disclose exact number of shares shorted per firm in real time.
1 · Reply
resq1
resq1 Feb. 5 at 10:40 PM
$OMER you guys all know that it's not every day that a rare disease drug gets full FDA approval w/o black label warnings and approved for pediatric patients, right?
1 · Reply
in_GOD_alone
in_GOD_alone Feb. 5 at 10:09 PM
$OMER need a beer y’all.
0 · Reply
What_the_heck_is_that
What_the_heck_is_that Feb. 5 at 8:39 PM
$OMER it's one thing to be down in sympathy with the market but to steadily watch a slow crash since the first of the year in the absence of any negative news whatsoever is just mind boggling. I'm also not exactly sure why the next ER has to occur at the tail end of March either, since the last one was in Nov 2025 and 3 months later would logically put a 'quarterly' report sometime in Feb, not March, and especially not the very last day of March as anticipated 🤷. Regardless, it's going to take hard sales figures to drive this upward, not just a PR that says "hey, we're distributing the product". That unfortunately leaves room for speculation that the drug might not be getting the expected traction. I'm holding on still but those who sold at $17+ at least made decent profit even if the SP climbs higher in the future. You won't go broke selling over your average but you definitely could go broke hanging on for dear life wondering what's wrong.
3 · Reply
Holdyn_Baggins
Holdyn_Baggins Feb. 5 at 8:38 PM
$ONDS $OMER $IBRX sweet baby Moses… 🤣😂😵‍💫😘
0 · Reply
MattyMoMo
MattyMoMo Feb. 5 at 8:32 PM
$OMER OMER is being treated like an AI or tech stock today.
0 · Reply
mjk49
mjk49 Feb. 5 at 8:28 PM
$OMER @ipdamages Is this dropping this low because of trumpRX and news related to that?
1 · Reply
BioBomber
BioBomber Feb. 5 at 8:28 PM
$OMER We were higher than this 2 months ago before approval. It’s laughable at this point, bought another 5k shares.
0 · Reply
TRYII
TRYII Feb. 5 at 8:26 PM
$OMER I know what I have
0 · Reply
mjk49
mjk49 Feb. 5 at 8:09 PM
$OMER added more
0 · Reply
MazaBear
MazaBear Feb. 5 at 8:09 PM
$OMER Up 15% on the last 12 months despite FDA approval for one and only drug, confirmation of rapid sales and delivery + potentially upwards of $2.1B dollar deal with Novo for secondary drug. Yeah, this is fucking wild it's so undercooked!
4 · Reply
StockMktGuru
StockMktGuru Feb. 5 at 8:05 PM
$OMER Amazing silence from Greg as usual. Where is the $100M ?
1 · Reply
LeaLeb
LeaLeb Feb. 5 at 8:02 PM
$OMER Just bought another 10k shares thanks shorties. We're close to a bottom highly doubt we going for gap fill in the 8's.
0 · Reply
BrianRix
BrianRix Feb. 5 at 7:55 PM
$OMER down in sympathy with $NVO? Stupid markets. I have no dry powder to add
1 · Reply
AgentMulder
AgentMulder Feb. 5 at 7:49 PM
$OMER Damn SP makes no sense, even if lowball Revs for Yart, what about the NVO 2.1B deal??? No value attributed to that is pure BS…..we patiently wait for accurate valuation, no doubt coming soon 🔜 😎
2 · Reply
DarthTrader75
DarthTrader75 Feb. 5 at 7:32 PM
$OMER below 10 I will add ( again ) more… but this is really crazy… averaging down but still 28% red 😁
0 · Reply
StayHumbleBeKind
StayHumbleBeKind Feb. 5 at 7:14 PM
$OMER I’m in. I like the valuation and the future looks bright!
0 · Reply
resq1
resq1 Feb. 5 at 7:11 PM
$OMER 11:11 make a wish
1 · Reply
syncnode
syncnode Feb. 5 at 7:00 PM
$OMER Know what you have! i.e. Zaltenibart! Clinical data indicates that zaltenibart (OMS906) may offer a competitive efficacy profile in the PNH market, particularly in its ability to normalize hemoglobin levels, though it currently faces established oral and subcutaneous competitors like Fabhalta and Empaveli, and standard of care - Eculizumab (Soliris).
1 · Reply
naturegirl669
naturegirl669 Feb. 5 at 6:48 PM
$OMER - Anybody else have some respectable LOW BALL revenue numbers? How do we get to $500M in revs in US for Yart? In 2023, a total of 23,152 hematopoietic cell transplantations (HCTs) (blood stem cell transplants) were performed in the United States and reported to the CIBMTR. Let's say we lower the average total doses to 7. That would be 250K a patient. We are only going to count only allogeneic patients(so we're going to try and LOW BALL) the revs. "In 2023, the number of allogeneic hematopoietic stem cell transplants (HSCT) in the United States exceeded 15,000, continuing a trend of high-volume, life-saving procedures for blood cancers and other disorders. Data indicates that allogeneic procedures represent a significant portion of the roughly 20,000+ total annual transplants, which also include autologous procedures." $500M divide by $250K = 2000 TMA patients That is 2000 allogeneic patients out 15000 (2023 numbers) or 13.3% of the total allogeneic patients with 7 doses. So 4000 patients?
2 · Reply